人GLP-1类似物治疗2型糖尿病的研究进展  

Research progress of human GLP-1 analogues for type 2 diabetes

作　　者：蒋筠[1] 彭永德[1] 

机构地区：[1]上海交通大学附属第一人民医院内分泌科,上海200080

出　　处：《世界临床药物》2010年第2期74-77,97,共5页World Clinical Drug

摘　　要：人胰高血糖素样肽1(GLP-1)类似物已成为新一代降糖药。无论是上市的艾塞那肽和利拉鲁肽,还是处于临床研究阶段的taspoglutide,均在2型糖尿病临床研究中取得显著成果,如有效降糖、减轻体重和减少低血糖发生等。同时,人GLP-1类似物潜在的益处与风险还有待进一步研究。Human glucagon-like peptide-1 （GLP-1）analogues have become the new generation of hypoglycemic agents. Exenatide and liraglutide are already on the market. Taspoglutide is currently moving into phase 3 clinical trials. All of them have been proven effective in the treatment of type 2 diabetes, such as improvement in glycemia control, weight loss, a low incidence of hypoglycemia. Potential benefits and risks of human GLP-1 analogues require further study. This review described the progress on human GLP-1 analogues for type 2 diabetes and their clinical application.

关 键 词：2型糖尿病 肠促胰素 胰高血糖素样肽1 类似物 

分 类 号：R977.15[医药卫生—药品]